Evidence map›Paper›PMID 27073073›Full record

ArticleDigestive diseases and sciences2016

Ischemic Colitis as a Complication of Medication Use: An Analysis of the Federal Adverse Event Reporting System.

Klaus Bielefeldt

Abstract read
PubMed Publisher
In one paragraph

Article in Digestive diseases and sciences, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Colonoscopy-related colonic ischemia.World journal of gastroenterology · 2021
    Review
  5. Diagnostic methods and drug therapies in patients with ischemic colitis.International journal of colorectal disease · 2021
    Review
  6. Overcoming cancer therapeutic bottleneck by drug repurposing.Signal transduction and targeted therapy · 2020
    Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Klaus BielefeldtDivision of Gastroenterology, University of Pittsburgh Medical Center, Pittsburgh, PA, 15213, USA. bielefeldtk@upmc.edu.ORCID 0000-0003-4972-6518
University of Pittsburgh Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMore than one decade ago, rising cases of ischemic colitis (IC) prompted the Federal Drug Administration to revoke alosetron's approval as treatment of irritable bowel syndrome (IBS). The aim of this study was to identify medical therapies associated with development of IC.

methodsThe Federal Adverse Event Reporting System was queried for the time between January 2004 and September 2015. We identified reports listing IC as treatment complication and extracted suspected causative and concomitantly administered drugs, indications for their use and outcomes.

resultsAfter eliminating duplicates, we found 2811 cases of IC (68.4 % women; 59.4 ± 0.4 years). Patients with IBS accounted for 3.9 % of the cases, mostly attributed to tegaserod or alosetron. Chemotherapeutic and immunosuppressive drugs, sex hormones, and anticoagulants were the most commonly suspected causes. Bisphosphonates, nonsteroidal anti-inflammatory drugs, antipsychotics, triptans, interferon therapy, and laxative use prior to colonoscopy were among the more commonly listed treatments. In 8 %, the adverse event contributed to the patient's death with male sex and older age predicting fatal outcomes.

conclusionBeyond confirming known risks of IC, the results identified several potential culprits of ischemic colitis. This information may not only explain the development of this serious adverse event, but could also guide treatment decisions, cautioning healthcare providers when considering these agents in persons with known risk factors or other drugs that may increase their risk of IC.

Indexed as

Adverse Drug Reaction Reporting SystemsAgedAge FactorsAnticoagulantsAnti-Inflammatory Agents, Non-SteroidalAntineoplastic AgentsAntipsychotic AgentsAutoimmune DiseasesBone Density Conservation AgentsCarbolinesColitis, IschemicColonoscopyDatabases, FactualDiphosphonatesEstrogensFemalealosetronAnticoagulantsAnti-Inflammatory Agents, Non-SteroidalAntineoplastic AgentsAntipsychotic AgentsBone Density Conservation AgentsCarbolinesDiphosphonatesEstrogensGonadal Steroid HormonesImmunosuppressive AgentsIndolesInterferonsLaxativesSerotonin AgentsSerotonin AntagonistsSerotonin Receptor AgoniststegaserodTryptaminesAlosetronColonoscopyInterferonTegaserodTreatment complicationTriptans

Identifiers

PMID27073073
OpenAlexW2337464124

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.